STOCK TITAN

Acumen Pharmaceuticals Inc - ABOS STOCK NEWS

Welcome to our dedicated news page for Acumen Pharmaceuticals (Ticker: ABOS), a resource for investors and traders seeking the latest updates and insights on Acumen Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Acumen Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Acumen Pharmaceuticals's position in the market.

Rhea-AI Summary
Acumen Pharmaceuticals presents comprehensive clinical and biomarker data for Sabirnetug (ACU193) at the American Academy of Neurology 2024 Annual Meeting. The presentation includes insights on safety profile, target engagement, and biomarker changes. Sabirnetug, a humanized monoclonal antibody, shows potential as a next-generation treatment for early Alzheimer's disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
none
-
Rhea-AI Summary
Acumen Pharmaceuticals partners with Lonza for manufacturing of sabirnetug, a monoclonal antibody targeting toxic soluble amyloid beta oligomers in Alzheimer's disease. Sabirnetug enters Phase 2 clinical trial in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
none
-
Rhea-AI Summary
Acumen Pharmaceuticals, Inc. (ABOS) reported financial results for 2023, highlighting Phase 1 success with sabirnetug in Alzheimer's disease treatment. The company plans to initiate Phase 2 and subcutaneous dosing studies in 2024. Cash reserves of $306.1 million support operations till 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags
Rhea-AI Summary
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) is set to present data from its Phase 1 INTERCEPT-AD study evaluating sabirnetug (ACU193) in early Alzheimer's disease at the American Academy of Neurology Annual Meeting. The company's sabirnetug is the first humanized monoclonal antibody to engage AβOs, a toxic form of amyloid beta. Acumen aims to deepen insights into safety, target engagement, and biomarker findings from the study. The company plans to initiate a Phase 2 trial for sabirnetug in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.34%
Tags
conferences
-
Rhea-AI Summary
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will report Q4 and year-end 2023 financial results on March 26, 2024. The company focuses on developing a therapeutic for Alzheimer's disease targeting toxic soluble amyloid beta oligomers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.75%
Tags
conferences earnings
-
Rhea-AI Summary
Acumen Pharmaceuticals, Inc. (ABOS) will participate in a fireside chat at Stifel 2024 CNS Days to discuss their novel therapeutic for Alzheimer's disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.58%
Tags
conferences
Rhea-AI Summary
Acumen Pharmaceuticals, Inc. presents positive CSF biomarker data supporting sabirnetug's efficacy in early Alzheimer's disease at the International Conference on Alzheimer's and Parkinson's Diseases. The Phase 1 trial results demonstrate sabirnetug's proof-of-mechanism and potential as a next-generation treatment for AD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Acumen Pharmaceuticals presents positive data on sabirnetug (ACU193) targeting soluble amyloid beta oligomers for Alzheimer's disease treatment at upcoming AD/PD conference. Sabirnetug shows potential in Phase 1 trial with well-tolerated, safe profile and significant amyloid plaque reduction. Phase 2 trial set to start in 2024. Company to share biomarker and target engagement data in oral and poster presentations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
conferences clinical trial
-
Rhea-AI Summary
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) has appointed James Doherty, Ph.D., as President and Chief Development Officer. Dr. Doherty brings extensive experience in CNS drug development and neuroscience-focused research. His responsibilities will include oversight of clinical and non-clinical development, chemistry, manufacturing & controls, and regulatory functions. Previously, Dr. Doherty served as Chief Development Officer at Sage Therapeutics, achieving U.S. FDA approvals for two treatments for postpartum depression. His appointment marks a pivotal moment for Acumen as they advance ACU193 as a potential best-in-class treatment for Alzheimer's disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
management
Rhea-AI Summary
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will present at the 42nd Annual J.P. Morgan Healthcare Conference to discuss their novel therapeutic for Alzheimer’s disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Acumen Pharmaceuticals Inc

Nasdaq:ABOS

ABOS Rankings

ABOS Stock Data

210.28M
32.28M
9.13%
72.62%
2.06%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Charlottesville

About ABOS

acumen is forging a new path towards safe and effective treatments for alzheimer’s disease and other neurodegenerative diseases through our focus on the biology of toxic amyloid-beta oligomers. our founders pioneered seminal discoveries and methods to understand the role of toxic amyloid-beta oligomers (aβo) in synaptic dysfunction and neurodegeneration. these early insights have fostered decades of research on the biology of aβo at acumen and throughout the field. we are now on the on cusp of realizing the therapeutic potential of aβo targeted drugs.